期刊文献+

肿瘤坏死因子转化酶(TACE)抑制剂的研究进展 被引量:2

Recent advance on tumor necrosis factor-α converting enzyme(TACE) inhibitors
下载PDF
导出
摘要 肿瘤坏死因子转化酶(TACE)已经成为治疗关节炎、癌症、糖尿病和HIV恶病质等疾病的一种潜在新靶点。通过对国外近几年来出现的新型TACE小分子抑制剂的介绍,旨在对现有抑制剂进行筛选和结构改造,进一步提高TACE抑制剂的选择性,降低体内代谢毒性。 Tumor necrosis factor (TNF)-converting enzyme (TACE) has emerged as a potential therapeutic target in the areas of arthritis, cancer, diabetes and HIV cachexia. The recent advance of the study on TACE inhibitors, which describes the discovery of some new small molecule TACE inhibitors, is reviewed in this article.
出处 《中国药物化学杂志》 CAS CSCD 2006年第3期188-192,共5页 Chinese Journal of Medicinal Chemistry
关键词 药物化学 构效关系 综述 小分子抑制剂 肿瘤坏死因子-α转化酶 medicinal chemistry SAR review small molecule inhibitors tumor necrosis factor-α convering enzyme
  • 相关文献

参考文献14

  • 1Kathleen ES. TNF and TNF-α inhibitors: mechanisms of action [ J ]. Pediatr Rheum Online J, 2004,(2):7- 22. 被引量:1
  • 2Peter JB, Trevor TH. Prospects for new drugs for chronic obstructive pulmonary disease [ J ]. Seminar,2004, 364(3) :985 - 996. 被引量:1
  • 3Marcia LM, Judith MW, Millard HL, et al. TACE and other ADAM proteases as targets for drug discovery[J]. DDT, 2001,6(8) :417 - 426. 被引量:1
  • 4Roy AB. Molecules in focus: Tumor necrosis factor-α converting enzyme[J]. Int J Biochem Cell Biol, 2002,34(7):1 -5. 被引量:1
  • 5Borrell PM, Rojo F, AlbaneU J, et al. TACE is required for the activation of the EGFR by TGF-alpha in tumors[J]. EMBO J, 2003, 22(5) : 1114 - 1124. 被引量:1
  • 6Meng HL, Vandana V, Klaus M, et al. The C-terminal domains of TACE weaken the inhibitory action of N-TIMP-3 [ J ]. FFBS Lett, 2002, 520 ( 4 ) : 102 -106. 被引量:1
  • 7James MC, Guixian J, Amy S, et al. Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 1:structure-based design of novel acetylenic P10 groups[J]. Bioorg Med Chem Lett, 2002, 12 (2):1195-1198. 被引量:1
  • 8Xue CB, He XH, Roderick J, et al. Rational design ,synthesis and structure-activity relationships of a cyclic succinate series of TNF-α converting enzyme inhibitors. Part 1 : lead identification [ J ]. Bioorg Med Chem Lett, 2003, 13(9) :4293 - 4297. 被引量:1
  • 9Xue CB, He XH, Roderick J, et al. Rational design,synthesis and structure-activity relationships of a cyclic succinate series of TNF-α converting enzyme inhibitors. Part 2 : lead optimization [ J ]. Bioorg Med Chem Lett, 2003, 13(9) :4299 - 4304. 被引量:1
  • 10Xue CB, He XH, Roderick J, et al. Synthesis and structure-activity relationship of a novel sulfone series of TNF-α converting enzyme inhibitors [J ]. Bioorg Med Chem Lett, 2004, 14 (17) : 4453 - 4459. 被引量:1

同被引文献42

  • 1Liliana Pérez.Inhibitory role of TACE/ADAM17 cytotail in protein ectodomain shedding[J].World Journal of Biological Chemistry,2011,2(11):246-251. 被引量:2
  • 2CHOY E H S, PANAYI G S N. Cytokine pathways and joint inflammation in rheumatoid arthritis [ J ]. N Engl J Med,2001, (344) :907 -916. 被引量:1
  • 3GARRISON L, MCDONNELL N D. Etanercept: therapeutic use in patients with rheumatoid arthritis [J]. Ann Rheum Dis, 1999,58 ( Suppl. 1 ) : 165 - 169. 被引量:1
  • 4NELSON F C, SANTOS E D. Benzodiazepine inhibitors of the MMPs and TACE[ J].Bioorg Med Chem Lett,2002,12 (20) :2867 - 2877. 被引量:1
  • 5ELLIOTT S ,CAWSTON T. The clinical potential of matrix metalloproteinase inhibitors in the rheumatic disorders [ J]. Drugs Aging,2001,18 (2) :87 - 99. 被引量:1
  • 6SHAW T S, NIXON J S, BOTTOMLEY K M. Metalloproteinase inhibitors: new opportunities for the treatment of rheumatoid arthritis and osteoarthritis [J]. Exp Opin Invest Drugs,2000,9 (7) : 1469 - 1478. 被引量:1
  • 7AGGARWAL B B, KOHR W J, HASS P E, et al. Human tumor necrosis factor. Production, purification, and characterization [ J ]. Biol Chem, 1985,260 (4) :2345 - 2354. 被引量:1
  • 8TRACEY K J, CERAMI A. Tumour necrosis factor: a pleiotropic cytokine and therapeutic target[ J]. Annu Rev Med, 1994,45:491 -503. 被引量:1
  • 9AGGARWAL B B, NATARAJAN K. Tumor necrosis factors: developments during the last decade. [ J ]. Euro Cytokine Netw, 1996,7 (2) :93 -124. 被引量:1
  • 10BEMELMANS M H A,VAN TITS L J H,BUURMAN W A. Tumor necrosis factor: function, release and clearance [ J ]. Crit Rev Immunol, 1996,16 ( 1 ) : 1 -11. 被引量:1

引证文献2

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部